Historical record - last NADAC effective date: 5/22/2019
Product Information
VENLAFAXINE HCL 37.5 MG TABLET is a generic product labeled by Heritage Pharmaceuticals Inc., priced at $0.1699 per EA under NDC 23155024709. Its NADAC has been published 260 times since Jun 4, 2014.
FDA first approved this application on Jan 9, 2009. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
37.5 mg/1
Manufacturer
Heritage Pharmaceuticals Inc.NDC
23155024709
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
5/22/2019
Active Ingredients
VENLAFAXINE HYDROCHLORIDEApproval Type
Generic (ANDA)
FDA Application
ANDA078554FDA Approved
1/9/2009
TE Code
AB
On Market Since
7/19/2021
Pharmacological Classes
Price Statistics
The NADAC for VENLAFAXINE HCL 37.5 MG TABLET has been published 260 times since Jun 4, 2014, and over the history we have for it it has declined 45.5%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.1699 per EA |
|---|---|
| All-time high | $0.4135 (Jan 13, 2016) |
| All-time low | $0.1586 (Feb 20, 2019) |
| Median price | $0.2730 |
| Average price | $0.2617 |
| Largest weekly change | +32.1% (Apr 19, 2017) |
| Weeks tracked | 260 |
| Tracking since | Jun 4, 2014 |
1W
N/A
1M
N/A
3M
N/A
6M
N/A
1Y
N/A
3Y
N/A
5Y
N/A
All
-45.5%
Last surveyed May 22, 2019 — this NDC no longer appears in the current weekly NADAC file.
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 58% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Heritage Pharmaceuticals Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
VENLAFAXINE market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Serotonin and Norepinephrine Reuptake Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of VENLAFAXINE HCL 37.5 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for VENLAFAXINE HCL 37.5 MG TABLET, manufactured by Heritage Pharmaceuticals Inc., is $0.1699 per EA (NDC 23155024709), effective May 22, 2019.
How has the price of VENLAFAXINE HCL 37.5 MG TABLET changed over time?
Over the history we have for it, the NADAC for VENLAFAXINE HCL 37.5 MG TABLET has declined 45.5%. It has been tracked across 260 weekly CMS publications since Jun 4, 2014.
What are the highest and lowest recorded NADAC prices for VENLAFAXINE HCL 37.5 MG TABLET?
Since Jun 4, 2014, the NADAC for VENLAFAXINE HCL 37.5 MG TABLET has ranged from a low of $0.1586 (Feb 20, 2019) to a high of $0.4135 (Jan 13, 2016), with a median of $0.2730 per EA.
Are there cheaper alternatives to VENLAFAXINE HCL 37.5 MG TABLET?
Yes. 1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, VENLAFAXINE HCL 37.5 MG TABLET, is $0.0714 per EA — about 58% below VENLAFAXINE HCL 37.5 MG TABLET.
Who manufactures VENLAFAXINE HCL 37.5 MG TABLET?
VENLAFAXINE HCL 37.5 MG TABLET (NDC 23155024709) is labeled by Heritage Pharmaceuticals Inc., and CMS classifies it as a generic product.